Who are ACT-539313's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone tablets, Risperidone, Haloperidol, Risperdal Consta, Risperidone, divalproex, Risperidone Long Acting, Aripiprazole or other oral antipsychotics.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/act-539313.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ACT-539313 — Competitive Intelligence Brief

ACT-539313 (ACT-539313) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D2 receptor antagonist. Area: Psychiatry.

phase 2 Dopamine D2 receptor antagonist D2 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

ACT-539313 (ACT-539313) — Idorsia Pharmaceuticals Ltd.. ACT-539313 is a selective dopamine D2 receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ACT-539313 TARGET	ACT-539313	Idorsia Pharmaceuticals Ltd.	phase 2	Dopamine D2 receptor antagonist	D2 receptor
Risperidone tablets	Risperidone tablets	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Risperidone, Haloperidol	Risperidone, Haloperidol	Ludwig-Maximilians - University of Munich	marketed	Antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperdal Consta	Risperdal Consta	Zogenix, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone, divalproex	Risperidone, divalproex	Nathan Kline Institute for Psychiatric Research	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	Dopamine D2 receptor (risperidone); histone deacetylase / GABA pathway (divalproex)
Risperidone Long Acting	Risperidone Long Acting	Dartmouth-Hitchcock Medical Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Aripiprazole or other oral antipsychotics	Aripiprazole or other oral antipsychotics	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (agonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D2 receptor antagonist class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Idorsia Pharmaceuticals Ltd. · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACT-539313 — Competitive Intelligence Brief. https://druglandscape.com/ci/act-539313. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab